BURSTEIN; Ethan S.

Patent Applications and Registrations

Patent applications and USPTO patent grants for BURSTEIN; Ethan S..The latest application filed is for "compounds, salts thereof and methods for treatment of diseases".

Company Profile

1.5.18

BURSTEIN; Ethan S. - San Diego CA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Compounds, Salts Thereof And Methods For Treatment Of Diseases App 20220298151 - BURSTEIN; Ethan S. ; et al.	2022-09-22
Pimavanserin For Treating Schizophrenia Or For Treating Psychosis Secondary To Neurodegenerative Disorders Or Depressive Disorder App 20220288048 - Kirola; Dragana Bugarski ; et al.	2022-09-15
Compounds, salts thereof and methods for treatment of diseases Grant 11,440,884 - Burstein , et al. September 13, 2	2022-09-13
Compounds, salts thereof and methods for treatment of diseases Grant 11,345,693 - Burstein , et al. May 31, 2	2022-05-31
Methods Of Treating Depression, Anxiety And Sexual Dysfunction Using The Compound Pimavanserin App 20220016101 - Burstein; Ethan S. ; et al.	2022-01-20
5-ht2a Serotonin Receptor Inverse Agonists Or Antagonists For Use In Reducing Amyloid-beta Peptides And Accumulation Of Amyloid Plaques App 20220000852 - Burstein; Ethan S.	2022-01-06
Pimavanserin for treating impulse control disorder Grant 11,135,211 - Burstein October 5, 2	2021-10-05
Compounds, Salts Thereof And Methods For Treatment Of Diseases App 20210122713 - BURSTEIN; Ethan S. ; et al.	2021-04-29
Compounds, Salts Thereof And Methods For Treatment Of Diseases App 20200270239 - BURSTEIN; Ethan S. ; et al.	2020-08-27
Pimavanserin For Treating Impulse Control Disorder App 20200061045 - Burstein; Ethan S.	2020-02-27
Muscarinic agonists Grant 9,670,209 - Burstein , et al. June 6, 2	2017-06-06
Treatment Of A Neurodegenerative Disease Or Disorder App 20160263189 - Burstein; Ethan S.	2016-09-15
Muscarinic Agonists App 20160039819 - BURSTEIN; Ethan S. ; et al.	2016-02-11
Treatment Of Neurodegenerative Diseases App 20140329903 - Burstein; Ethan S. ; et al.	2014-11-06
Phenylpiperidine Compounds For The Treatment Of Neurological And Psychiatric Disorders App 20130197032 - Carlsson; Lizzie Maria ; et al.	2013-08-01
Enabling Methods To Identify Allosteric Modulators Of Receptor Activity App 20090209525 - Spalding; Tracy A ; et al.	2009-08-20
G-protein Coupled Receptors High-throughput Functional Assay App 20080280303 - Burstein; Ethan S. ; et al.	2008-11-13
Clinical indications for genotyping polymorphic variants of G-protein coupled receptors Grant 7,348,140 - Weiner , et al. March 25, 2	2008-03-25
Bicyclic-nitrogen Compounds As Modulators Of Ghrelin Receptor And Uses Thereof App 20070213359 - Burstein; Ethan S. ; et al.	2007-09-13
Use of N-desmethylclozapine and related compounds as dopamine stabilizing agents App 20060252744 - Burstein; Ethan S.	2006-11-09
G-protein coupled receptors high-throughput functional assay App 20050123964 - Burstein, Ethan S. ; et al.	2005-06-09

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.